cyclosporine and eye
cyclosporine has been researched along with eye in 55 studies
Research
Studies (55)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (16.36) | 18.2507 |
| 2000's | 16 (29.09) | 29.6817 |
| 2010's | 25 (45.45) | 24.3611 |
| 2020's | 5 (9.09) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Castillo, J; Cristobal, JA; Dapena, MP; Minguez, E; Palomar, A; Tiestos, MT | 1 |
| Kawashima, H; Mochizuki, M | 1 |
| Acezat-Mispelter, F; Goizel, C; Humbert, H; Lundh, RL; Pouliquen, Y; Vernillet, L | 1 |
| Bahn, RS; Gorman, CA; Heufelder, AE | 1 |
| Cheng, YL; Oh, C; Rootman, DS; Saville, BA | 1 |
| Barak, V; BenEzra, D; Kalichman, I; Maftzir, G | 1 |
| Ashton, P; Cordahi, GJ; Grossniklaus, H; Jaffe, GJ; Martin, DF; Pearson, PA; Schmeisser, ET | 1 |
| Acheampong, A; Andersen, J; Angelov, O; Brar, B; Wiese, A; Yuan, Y | 1 |
| Acheampong, AA; Decker, R; Ding, S; Shackleton, M; Stern, ME; Tang-Liu, DD | 1 |
| Halford, WP; Schaffer, PA | 1 |
| Kajikawa, T; Mishima, HK; Murakami, T; Takano, M | 1 |
| Alonso, MJ; De Campos, AM; Sánchez, A | 1 |
| Ibuki, H; Kawashima, Y; Kuwano, M; Morikawa, N; Ota, A | 1 |
| Fukumura, M; Hasegawa, M; Ikeda, Y; Inomata, H; Ishibashi, T; Kato, A; Nagai, Y; Sakamoto, T; Sueishi, K; Ueno, H; Yonemitsu, Y | 1 |
| Shi, W; Wang, S; Xie, L | 1 |
| Choi, D; Raisman, G | 1 |
| Behar-Cohen, F; Besseghir, K; Felt-Baeyens, O; Gurny, R; Lallemand, F | 1 |
| Cimino, L; Finzi, G; Gandolfi, SA; Mora, P; Orsoni, JG; Zavota, L | 1 |
| Alonso, MJ; Sánchez, A | 1 |
| Davis, JL; Gilger, BC; Robinson, MR | 1 |
| Sheu, SJ; Yang, CA | 1 |
| Bungay, PM; Csaky, KG; de Monasterio, F; Dunn, JP; Gilger, BC; Kim, H; Lee, SS; Lutz, RJ; Robinson, MR; Tansey, G; Tremblay, M; Yuan, P | 1 |
| Acheampong, A; Tang-Liu, DD | 1 |
| Besseghir, K; Dumont, JM; Felt-Baeyens, O; Furrer, P; Gex-Fabry, M; Gurny, R; Lallemand, F | 1 |
| He, Y; Liu, YL; Ma, ZZ; Wang, JC; Zhang, Q; Zhu, XA | 1 |
| Başaran, E; Demirel, M; Sirmagül, B; Yazan, Y | 2 |
| Chauhan, A; Gupta, C | 1 |
| Aksungur, P; Demirbilek, M; Denkbaş, EB; Ludwig, A; Unlü, N; Vandervoort, J | 1 |
| Choi, HG; Han, SD; Hwang, HD; Jang, SW; Kim, JH | 1 |
| Behar-Cohen, F; Di Tommaso, C; El Zaoui, I; Furrer, P; Guillarme, D; Gurny, R; Kaufmann, B; Rodriguez-Aller, M; Rudaz, S; Stella, C; Valamanesh, F; Veuthey, JL | 1 |
| Fiscella, RG | 1 |
| Aldouby, YH; Avramoff, A; Domb, AJ; Khan, W | 1 |
| Behar-Cohen, F; El Sanharawi, M; Guillarme, D; Gurny, R; Rodriguez-Aller, M; Veuthey, JL | 1 |
| Başaran, E; Berkman, MS; Büyükköroğlu, G; Yazan, Y; Yenilmez, E | 1 |
| Dutescu, RM; Merkel, OM; Panfil, C; Schrage, N | 1 |
| Chorążewicz, J; Kaliszan, R; Markuszewski, MJ; Radwańska, A; Siluk, D; Struck-Lewicka, W; Szerkus, O; Sznitowska, M; Wiczling, P; Wolska, E | 1 |
| Erdinest, N; Solomon, A | 1 |
| Clift, DE; Colwill, RM; Creton, R; Kapoor, M; LoPiccolo, MK; Passarelli, EA; Richendrfer, HA; Thorn, RJ | 1 |
| Barni, S; Calvani, A; Caputo, R; de Libero, C; di Grande, L; di Simone, L; Mori, F; Novembre, E; Pucci, N; Rusconi, F | 1 |
| Ulus, ND; Yücel, OE | 1 |
| Dai, Z; Hong, J; Liu, X; Sun, J; Sun, X; Yu, X | 1 |
| Chen, D; Li, Y; Shen, Y; Tu, J; Yang, W; Yu, Y | 1 |
| Chorążewicz, J; Kaliszan, R; Markuszewski, MJ; Raczyńska, K; Radwańska, A; Szerkus, O; Sznitowska, M; Wolska, E | 1 |
| Bevans, SL; Fowler, PG; Pavlidakey, PG; Sami, N; Stoll, M; Theos, AJ | 1 |
| Gote, V; Mandal, A; Mitra, AK; Ogundele, A; Pal, D | 1 |
| Gan, L; Liu, Y; Wang, Y; Yang, J; Zhang, H | 1 |
| Gore, A; Graham, R; Meller, R; Wu, K | 1 |
| Abul Kalam, M; Ali, R; Alshamsan, A; Alturki, TA; Binkhathlan, Z; Lavasanifar, A; Raish, M; Safaei Nikouei, N; Vakili, MR | 1 |
| Cantú-Rodríguez, OG; Garza-Acosta, AC; Gómez-Almaguer, D; Gómez-De León, A; González-Cantú, GA; González-Llano, O; González-Treviño, JL; Gutierrez-Aguirre, CH; Hawing-Zarate, JA; Herrera-Rojas, MA; Jaime-Pérez, JC; Mancías-Guerra, C; Martínez-Garza, DM; Sada-Ovalle, I; Vázquez-Mellado, A | 1 |
| Ashraf, M; Choi, S; Cruz, CN; Dong, Y; Hengst, L; Hunt, R; Patel, D; Vo, A; Xu, X | 1 |
| Gan, L; Wang, Q; Wu, Z; Xu, L; Yan, R; Zhang, H | 1 |
| Agarwal, N; Borkar, RM; Das, D; Deka, A; Goswami, A; Jala, A; Rahman, SNR; Shunmugaperumal, T; Singh, V; Sree, A; Venuganti, A | 1 |
| Ding, Z; Guan, Q; Li, Y; Liu, M; Liu, S; Wang, Q; Wang, Z; Xu, J; Zhang, H; Zhao, Y | 1 |
| Benival, D; Kolhe, S; Rana, D; Rawat, G; Salave, S | 1 |
Reviews
8 review(s) available for cyclosporine and eye
| Article | Year |
|---|---|
Cyclosporine A delivery to the eye: a pharmaceutical challenge.
Topics: Administration, Topical; Animals; Cyclosporine; Drug Carriers; Drug Delivery Systems; Eye; Eye Diseases; Humans | 2003 |
The potential of chitosan in ocular drug delivery.
Topics: Administration, Topical; Biocompatible Materials; Chitin; Chitosan; Cyclosporine; Drug Delivery Systems; Eye; Humans | 2003 |
Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.
Topics: Animals; Chemical Phenomena; Chemistry, Physical; Cyclosporine; Dry Eye Syndromes; Eye; Humans; Immunosuppressive Agents | 2005 |
Understanding dry eye disease: a managed care perspective.
Topics: Adrenal Cortex Hormones; Aging; Clinical Trials as Topic; Cyclosporine; Dietary Supplements; Eye; Fatty Acids, Essential; Humans; Immunosuppressive Agents; Keratoconjunctivitis Sicca; Managed Care Programs; Ophthalmic Solutions; Practice Guidelines as Topic; Quality of Life | 2011 |
Topical immunomodulators in the management of allergic eye diseases.
Topics: Administration, Topical; Adrenal Cortex Hormones; Conjunctivitis, Allergic; Cyclosporine; Eosinophils; Eye; Humans; Immunomodulation; Lymphocyte Activation; Mast Cells; T-Lymphocytes; Tacrolimus; Treatment Outcome | 2014 |
Pediatric ocular lichen planus and lichen planopilaris: One new case and a review of the literature.
Topics: Child; Cyclosporine; Eye; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lichen Planus; Methotrexate; Prednisolone; Scalp; Scalp Dermatoses | 2018 |
Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.
Topics: Administration, Ophthalmic; Clinical Trials, Phase III as Topic; Cyclosporine; Dry Eye Syndromes; Eye; Humans; Immunosuppressive Agents; Micelles; Nanoparticles; Ophthalmic Solutions; Treatment Outcome | 2019 |
Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems.
Topics: Administration, Ophthalmic; Cyclosporine; Drug Delivery Systems; Excipients; Eye; Eye Diseases; Humans; Immunosuppressive Agents | 2023 |
Trials
2 trial(s) available for cyclosporine and eye
| Article | Year |
|---|---|
[Intraocular absorption of cyclosporin A eyedrops].
Topics: Aqueous Humor; Cornea; Corneal Transplantation; Cyclosporine; Eye; Graft Rejection; Humans; Ophthalmic Solutions | 1992 |
Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: A randomized, comparative, double-blind, crossover study.
Topics: Child; Conjunctivitis, Allergic; Creatinine; Cross-Over Studies; Cyclosporine; Disease Progression; Double-Blind Method; Drug Resistance; Eye; Female; Humans; Male; Ophthalmic Solutions; Quality of Life; Tacrolimus | 2015 |
Other Studies
45 other study(ies) available for cyclosporine and eye
| Article | Year |
|---|---|
Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat.
Topics: Animals; Antibodies; Antigens; Arrestin; Autoimmune Diseases; Body Weight; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; Eye; Eye Proteins; Guanidines; Immunosuppressive Agents; Male; Rats; Rats, Inbred Lew; Tacrolimus; Uveitis | 1990 |
Ocular distribution of cyclosporin A (Sandimmun) following systemic and topical administration to rabbits.
Topics: Administration, Topical; Animals; Cornea; Cyclosporine; Eye; Injections, Intramuscular; Male; Ophthalmic Solutions; Rabbits; Tears; Vitreous Body | 1991 |
Modulation of HLA-DR expression on retroocular fibroblasts from patients with active thyroid-related ophthalmopathy: in vitro effects of agents used in the management of hyperthyroidism and ophthalmopathy.
Topics: Cells, Cultured; Cyclosporine; Dexamethasone; Eye; Fibroblasts; Gene Expression; Graves Disease; HLA-DR Antigens; Humans; Indomethacin; Interferon-gamma | 1991 |
A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits.
Topics: Animals; Cornea; Cyclosporine; Drug Delivery Systems; Eye; Mathematics; Models, Chemical; Rabbits; Sclera; Tissue Distribution | 1995 |
Serum levels of interleukin-2 receptor in ocular Behçet's disease.
Topics: Behcet Syndrome; Cyclosporine; Drug Combinations; Eye; Eye Diseases; Humans; Methylprednisolone; Pars Planitis; Receptors, Interleukin-2; Reference Values | 1993 |
Evaluation of a delivery system providing long-term release of cyclosporine.
Topics: Animals; Biological Availability; Cataract; Cyclosporine; Delayed-Action Preparations; Drug Delivery Systems; Drug Evaluation; Drug Implants; Electroretinography; Eye; Female; Half-Life; Immunosuppressive Agents; Injections; Lens, Crystalline; Macaca fascicularis; Male; Rabbits; Retina; Tissue Distribution; Vitreous Body | 1996 |
Preclinical safety studies of cyclosporine ophthalmic emulsion.
Topics: Animals; Conjunctivitis; Cyclosporine; Dogs; Emulsions; Eye; Female; Male; Rabbits; Time Factors | 1998 |
Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.
Topics: Absorption; Administration, Topical; Animals; Ciliary Body; Conjunctiva; Cornea; Cyclosporine; Dogs; Dose-Response Relationship, Drug; Emulsions; Eye; Female; Iris; Lacrimal Apparatus; Lens, Crystalline; Male; Ophthalmic Solutions; Rabbits; Sclera; Tissue Distribution | 1999 |
Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo.
Topics: Animals; Chlorocebus aethiops; Cyclophosphamide; Cyclosporine; Disease Models, Animal; Eye; Genome, Viral; Herpes Simplex; Herpesvirus 1, Human; Immediate-Early Proteins; Immunosuppression Therapy; Immunosuppressive Agents; Mice; Mice, Inbred ICR; Mutagenesis; Trigeminal Ganglion; Ubiquitin-Protein Ligases; Vero Cells; Viral Load; Virus Latency; Virus Replication | 2000 |
Role of P-glycoprotein in ocular clearance of rhodamine 123 in rabbits.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Eye; Male; Rabbits; Rhodamine 123 | 2000 |
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.
Topics: Administration, Topical; Animals; Antifungal Agents; Chitin; Chitosan; Conjunctiva; Cornea; Cyclosporine; Drug Carriers; Drug Delivery Systems; Eye; Male; Microscopy, Electron; Mucous Membrane; Ophthalmic Solutions; Particle Size; Rabbits | 2001 |
Cyclosporine A formulation affects its ocular distribution in rabbits.
Topics: Animals; Cyclosporine; Drug Carriers; Eye; Immunosuppressive Agents; Instillation, Drug; Male; Rabbits; Solubility; Tissue Distribution | 2002 |
Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure.
Topics: Adenoviridae; Animals; Cell Line; Cyclosporine; Dexamethasone; DNA, Recombinant; Eye; Gene Expression; Gene Transfer Techniques; Humans; Lac Operon; Male; Rats; Rats, Wistar; Retina; Sendai virus; T-Lymphocytes, Cytotoxic | 2002 |
[Prolongation of corneal allograft survival in mice with a cyclosporine drug delivery system implant].
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cornea; Corneal Transplantation; Cyclosporine; Drug Delivery Systems; Drug Implants; Eye; Graft Survival; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Time Factors | 2002 |
Immune rejection of a facial nerve xenograft does not prevent regeneration and the return of function: an experimental study.
Topics: Animals; Cyclosporine; Drug Administration Routes; Eye; Facial Nerve; Facial Nerve Injuries; Immunosuppression Therapy; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Microscopy, Electron; Motor Neurons; Nerve Regeneration; Neutrophils; Rats; Rats, Inbred Strains; Recovery of Function; Schwann Cells; Sciatic Nerve; Staining and Labeling; Tissue Transplantation; Transplantation, Heterologous | 2003 |
Effect of a drug combination treatment on ocular perfusion in recurrent idiopathic intermediate uveitis.
Topics: Adult; Blood Flow Velocity; Ciliary Arteries; Cortisone; Cyclosporine; Drug Therapy, Combination; Eye; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Methotrexate; Ophthalmic Artery; Perfusion; Prospective Studies; Recurrence; Regional Blood Flow; Retinal Artery; Ultrasonography, Doppler, Color; Uveitis, Intermediate; Visual Acuity | 2003 |
Novel approaches to ocular drug delivery.
Topics: Animals; Cyclosporine; Drug Administration Routes; Drug Delivery Systems; Eye; Eye Diseases; Genetic Therapy; Humans; Prodrugs; Prostheses and Implants | 2004 |
Macular hole in Behcet's disease.
Topics: Adrenal Cortex Hormones; Adult; Behcet Syndrome; Cyclosporine; Eye; Humans; Infant; Male; Pain; Papilledema; Retinal Hemorrhage; Retinal Perforations; Treatment Outcome; Vision Disorders | 2004 |
Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.
Topics: Animals; Biological Availability; Cyclosporine; Dogs; Drug Evaluation, Preclinical; Drug Implants; Electroretinography; Eye; Female; Graft vs Host Disease; Immunosuppressive Agents; Keratoconjunctivitis; Male; Rabbits; Retina; Safety; Sclera | 2005 |
A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics.
Topics: Administration, Topical; Animals; Cyclosporine; Drug Tolerance; Eye; Immunosuppressive Agents; Male; Prodrugs; Rabbits; Tears | 2005 |
Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits.
Topics: Animals; Aqueous Humor; Biocompatible Materials; Cyclosporine; Disease Models, Animal; Drug Carriers; Electroretinography; Eye; Immunosuppressive Agents; Injections; Lactic Acid; Leukocyte Count; Leukocytes; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Rabbits; Solubility; Uveitis | 2006 |
Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery.
Topics: Animals; Calorimetry, Differential Scanning; Cations; Cyclosporine; Delayed-Action Preparations; Eye; Immunosuppressive Agents; Lipids; Magnetic Resonance Spectroscopy; Nanoparticles; Ophthalmic Solutions; Particle Size; Sheep; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2010 |
Ophthalmic delivery of cyclosporine A by punctal plugs.
Topics: Cyclosporine; Delayed-Action Preparations; Dry Eye Syndromes; Eye; Humans; Immunosuppressive Agents; Methacrylates; Models, Biological; Prostheses and Implants; Prosthesis Design | 2011 |
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Topics: Animals; Biological Availability; Biological Transport; Cell Culture Techniques; Cell Line; Cell Survival; Cyclosporine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Dry Eye Syndromes; Eye; Fibroblasts; Immunosuppressive Agents; Kinetics; Male; Mice; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Rabbits; Solubility; Surface Properties; Tears | 2011 |
Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods.
Topics: Animals; Conjunctivitis; Cyclosporine; Drug Compounding; Drug Stability; Eye; Immunosuppressive Agents; Irritants; Male; Nanoparticles; Ophthalmic Solutions; Particle Size; Polymers; Rabbits; Solubility; Suspensions; Tears | 2011 |
In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Topics: Animals; Biological Availability; Chemistry, Pharmaceutical; Cyclosporine; Dry Eye Syndromes; Emulsions; Eye; Female; Kinetics; Ophthalmic Solutions; Prodrugs; Rabbits; Rats; Rats, Inbred Lew; Solubility; Tears; Water | 2012 |
Polymeric cyclosporine-A nanoparticles for ocular application.
Topics: Acrylic Resins; Animals; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cyclosporine; Eye; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Nanoparticles; Particle Size; Polymers; Sheep; Spectroscopy, Fourier Transform Infrared; Static Electricity; X-Ray Diffraction | 2011 |
Cyclosporin nanosphere formulation for ophthalmic administration.
Topics: Administration, Ophthalmic; Animals; Anti-Inflammatory Agents; Cyclosporine; Eye; Glycerol; Hexoses; Lecithins; Nanospheres; Pharmaceutical Vehicles; Polysorbates; Propylene Glycol; Rabbits; Solvents; Surface-Active Agents; Triglycerides | 2012 |
In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application.
Topics: Animals; Cyclosporine; Eye; Female; Immunosuppressive Agents; In Vitro Techniques; Ophthalmic Solutions; Permeability; Prodrugs; Rats; Rats, Inbred Lew; Spleen; Swine | 2013 |
Chitosan nanoparticles for ocular delivery of cyclosporine A.
Topics: Animals; Chitosan; Cyclosporine; Delayed-Action Preparations; Eye; Immunosuppressive Agents; Nanoparticles; Sheep | 2014 |
Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Topics: Administration, Topical; Alkanes; Animals; Castor Oil; Cornea; Cyclosporine; Drug Carriers; Eye; Eye Diseases; Fluorescein; Fluorine; Glucose; Inflammation; Kinetics; Lactic Acid; Lipids; Rabbits; Solvents | 2014 |
Development and validation of UHPLC method for the determination of cyclosporine A in biological samples.
Topics: Animals; Aqueous Humor; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cyclosporine; Eye; Immunosuppressive Agents; Lacrimal Apparatus; Male; Rabbits | 2014 |
Effects of embryonic cyclosporine exposures on brain development and behavior.
Topics: Animals; Behavior, Animal; Brain; Calcineurin Inhibitors; Cyclosporine; Eye; Female; Immunosuppressive Agents; Larva; Male; Pregnancy; Tacrolimus; Time Factors; Vision, Ocular; Zebrafish | 2015 |
Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis.
Topics: Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Child; Cohort Studies; Conjunctivitis, Allergic; Cornea; Cyclosporine; Drug Administration Schedule; Eye; Female; Humans; Immunosuppressive Agents; Male; Recurrence; Young Adult | 2016 |
Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis.
Topics: Animals; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Cyclosporine; Drainage; Drug Carriers; Drug Liberation; Eye; Fibroblasts; Fibrosis; Fluorescein Angiography; Glaucoma; Immunohistochemistry; Intraocular Pressure; Lactic Acid; Microscopy, Electron, Scanning; Neovascularization, Physiologic; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits; Thermogravimetry | 2016 |
Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
Topics: Administration, Ophthalmic; Animals; Biological Availability; Cell Line; Cyclosporine; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Dry Eye Syndromes; Eye; Freeze Drying; Humans; Immunosuppressive Agents; Micelles; Polyesters; Polyethylene Glycols; Powders; Rabbits; Technology, Pharmaceutical; Tissue Distribution | 2018 |
Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model.
Topics: Animals; Cyclosporine; Drug Carriers; Drug Liberation; Eye; Immunosuppressive Agents; Lipids; Male; Microspheres; Rabbits; Toxicity Tests, Acute | 2018 |
Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
Topics: Administration, Ophthalmic; Animals; Cations; Cyclosporine; Drug Liberation; Dry Eye Syndromes; Eye; Hexoses; Hyaluronic Acid; Immunosuppressive Agents; Liposomes; Male; Rabbits; Tears | 2019 |
Solubilization of Cyclosporine in Topical Ophthalmic Formulations: Preformulation Risk Assessment on a New Solid Form.
Topics: Castor Oil; Chemistry, Pharmaceutical; Cyclosporine; Excipients; Eye; Hydrogen Bonding; Micelles; Ophthalmic Solutions; Risk Assessment; Solubility; Solvents; Temperature; Water | 2019 |
Treatment of endotoxin-induced uveitis by topical application of cyclosporine a-loaded PolyGel™ in rabbit eyes.
Topics: Administration, Topical; Animals; Aqueous Humor; Cyclosporine; Drug Carriers; Eye; Immunosuppressive Agents; Lipopolysaccharides; Male; Polyesters; Rabbits; Uveitis | 2019 |
Cyclosporine A for the Prevention of Ocular Graft versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Is Safe and Feasible.
Topics: Cyclosporine; Eye; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies | 2020 |
Understanding drug distribution and release in ophthalmic emulsions through quantitative evaluation of formulation-associated variables.
Topics: Biological Transport; Cyclosporine; Diffusion; Drug Carriers; Drug Compounding; Drug Liberation; Emulsions; Eye; Fluprednisolone; Glycerol; Kinetics; Micelles; Models, Biological; Ocular Absorption; Ophthalmic Solutions; Phase Transition; Polysorbates; Surface Properties; Water | 2019 |
Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles.
Topics: Animals; Biological Availability; Crystallization; Cyclosporine; Diffusion; Drug Delivery Systems; Drug Liberation; Eye; Male; Mucus; Nanoparticles; Rabbits; Suspensions | 2021 |
Studies on spray dried topical ophthalmic emulsions containing cyclosporin A (0.05% w/w): systematic optimization, in vitro preclinical toxicity and in vivo assessments.
Topics: Animals; Chromatography, Liquid; Cyclosporine; Emulsions; Eye; Rabbits; Tandem Mass Spectrometry | 2023 |
Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation.
Topics: Cyclosporine; Drug Delivery Systems; Emulsions; Eye; Immunosuppressive Agents; Liposomes; Ophthalmic Solutions | 2023 |